NMN vs NR: Comparing NAD+ Precursors for Longevity and Cellular Health

A research-based comparison of NMN and NR as NAD+ precursors — covering the salvage pathway, Brenner and Yoshino human trial data, bioavailability debate, sublingual NMN, dose protocols, cost in the Australian market, and how to test NAD+ levels.

This article is intended for health professionals and informed patients. It does not constitute individual medical advice. NAD+ precursors are complementary medicines. Any supplementation strategy should be assessed in the context of your full clinical picture by a qualified practitioner.

The NMN vs NR debate has become one of the most active — and at times most confused — conversations in evidence-based longevity medicine. Both compounds are NAD+ precursors. Both are commercially available in Australia. Both have human clinical trial data. And yet supplement marketing routinely overstates what the science actually shows, leaving consumers and practitioners without the clarity they need to make sound decisions.

This article provides that clarity. We cover the NAD+ biosynthesis pathway, what the key human trials show for each precursor, the bioavailability debate that continues to generate controversy, practical dosing from published research, the Australian regulatory and market context, and how to monitor NAD+ levels if you choose to supplement. Where uncertainty exists, we name it — because in longevity medicine, intellectual honesty matters as much as the science itself.

1. Why NAD+ Declines With Age

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell in the body. It serves as an electron carrier in the mitochondrial electron transport chain, as a co-substrate for sirtuin enzymes (SIRT1–7) that regulate gene expression and stress responses, and as a substrate for PARP enzymes that repair DNA strand breaks.

The age-related decline in cellular NAD+ is one of the better-documented phenomena in biogerontology. Studies using blood, skin, and skeletal muscle biopsies consistently show that NAD+ concentrations fall by approximately 40–50% between the ages of 20 and 60 in humans. Skeletal muscle — a tissue with high metabolic demand — shows some of the steepest declines, with direct relevance to age-related sarcopenia and metabolic dysfunction.

Two mechanisms drive this decline:

Reduced biosynthesis: The rate-limiting enzyme in the NAD+ salvage pathway — NAMPT (nicotinamide phosphoribosyltransferase) — declines in activity with age, reducing the efficiency of NAD+ production from its precursors.

Increased consumption: CD38, an enzyme that degrades NAD+, increases markedly with chronic low-grade inflammation (inflammageing). PARP enzymes also hyperactivate in response to accumulating DNA damage in older cells, consuming large quantities of NAD+ in repair processes.

Both mechanisms operate simultaneously in aging tissue. This dual hit — less made, more consumed — creates the NAD+ deficit that NMN and NR supplementation aims to address.

The downstream consequences of NAD+ decline include impaired mitochondrial function, reduced sirtuin signalling (with effects on circadian rhythm regulation, metabolic flexibility, and stress resistance), and compromised DNA repair capacity. This mechanistic picture is what drives clinical interest in NAD+ precursor supplementation — and why the NMN vs NR question is worth answering carefully.

2. The NAD+ Salvage Pathway: NR → NMN → NAD+

To understand the NMN vs NR comparison, you need to understand where each compound sits in the biosynthesis cascade. Both enter what is known as the salvage pathway — the dominant route for NAD+ synthesis in adults.

The pathway proceeds as follows:

Nicotinamide riboside (NR) is phosphorylated by NRK1 or NRK2 kinases (nicotinamide riboside kinases) to produce nicotinamide mononucleotide (NMN)
NMN is then adenylated by NMNAT enzymes (NMNAT1, NMNAT2, or NMNAT3, depending on the cellular compartment) to produce NAD+

NR therefore sits two steps from NAD+. NMN sits one step from NAD+. This positional difference is the basis for claims that NMN is "more direct" or "faster" — but as the research shows, proximity in a biosynthetic pathway does not automatically confer clinical superiority.

The pathway also has a complicating feature at the point of cellular entry. NAD+ itself cannot cross cell membranes; cells must synthesise it internally. NR can enter cells via specific nucleoside transporters and is phosphorylated to NMN intracellularly. The debate around NMN concerns whether it can also enter cells directly, or whether it must first be dephosphorylated to NR extracellularly — effectively converting NMN into an NR prodrug before cellular uptake occurs.

This transport question is not merely academic. It is central to whether NMN and NR produce meaningfully different tissue distribution patterns — and therefore whether they should be used for different clinical indications.

3. The Bioavailability Debate: How Do NMN and NR Actually Enter Cells?

NR: A Clear Uptake Mechanism

NR has a well-established uptake mechanism. It is transported into cells via equilibrative nucleoside transporters (ENT1/ENT2), which are expressed across most mammalian tissues. Once inside the cell, NRK1/NRK2 phosphorylates NR to NMN, which is then converted to NAD+. This pathway has been confirmed in human cell culture, in animal models, and indirectly validated by the consistent blood NAD+ elevations observed in human oral NR trials.

NMN: The Transport Controversy

NMN is a larger, charged molecule compared to NR, and was initially assumed unable to cross cell membranes without first being dephosphorylated. The prevailing model held that orally administered NMN was converted to NR by gut ecto-5'-nucleotidases before intestinal absorption, making NMN functionally equivalent to NR at the point of cellular uptake.

In 2019, Grozio et al. (Nature Metabolism) identified a specific NMN transporter — encoded by the Slc12a8 gene — in mouse intestinal cells. This finding suggested that some tissues may take up NMN intact, bypassing the NR intermediate entirely. The paper generated significant controversy, with several groups raising concerns about the specificity of the proposed transporter and whether it operates at physiologically relevant concentrations.

As of 2026, the human relevance of the Slc12a8 transporter remains unconfirmed. What is established is:

Both NR and NMN raise NAD+ in human tissues, albeit with potentially different tissue distribution profiles
NMN may preferentially elevate NAD+ in skeletal muscle without producing large changes in circulating blood NAD+ — a finding from Yoshino et al. (2021) that has direct clinical implications
NR consistently and reproducibly elevates blood NAD+ by 40–60% in human trials
No published head-to-head human RCT has directly compared NR and NMN with matched doses and clinical outcome measures

The practical upshot: The transport debate matters for understanding mechanism, but both compounds are absorbed and raise tissue NAD+. The clinical question is which tissue — and which patient population — benefits most from each.

4. Human Trial Evidence: What the Research Actually Shows

NR Trials — The Brenner Research Programme

Dr Charles Brenner (University of Iowa) is the biochemist who first characterised NR as an NAD+ precursor in yeast and has been the central figure in NR clinical research. His group's work, alongside ChromaDex-funded trials, provides the strongest human evidence base for NR.

Trammell et al., 2016 (Nature Communications): The first human pharmacokinetic study of oral NR. Healthy adults received single doses of 100 mg, 300 mg, or 1,000 mg NR. Blood NAD+ metabolome increased in a dose-dependent manner within 2–4 hours of ingestion. NMN appeared as a downstream metabolite, confirming that the NR → NMN → NAD+ pathway operates in vivo in humans. This study established the fundamental pharmacokinetic proof of concept.

Martens et al., 2018 (Nature Communications): An 8-week randomised, double-blind, placebo-controlled trial in middle-aged and older adults (n=30, ages 55–79). Participants received 1,000 mg/day NR or placebo. Blood NAD+ concentrations increased approximately 60% in the NR group relative to placebo. A pre-specified subgroup analysis found reduced systolic blood pressure in participants with elevated baseline values. No significant improvements were observed in mitochondrial biogenesis markers or physical performance measures in this trial, highlighting the importance of realistic clinical expectations over 8 weeks.

Brenner & Minhas, 2021 (Trends in Molecular Medicine): A comprehensive review of NR's pharmacology, safety, and human trial data. The review notes that across multiple trials, NR at 250–2,000 mg/day shows a consistent and acceptable safety profile, with the most common adverse effects being mild gastrointestinal complaints at higher doses.

Dollerup et al., 2020 (American Journal of Clinical Nutrition): 12-week RCT, 2,000 mg/day NR vs placebo in overweight, middle-aged men (n=40). Blood NAD+ increased significantly in the NR group. However, no significant differences were observed in insulin sensitivity, body composition, skeletal muscle mitochondrial function, or other metabolic markers. This trial's null metabolic results at a high dose are an important counterpoint to mechanistic optimism — and underline that NAD+ elevation alone does not guarantee downstream metabolic improvement.

NMN Trials — The Yoshino Research Programme and Others

Yoshino et al., 2021 (Science): This is the landmark human NMN trial and one of the most discussed papers in the NAD+ field. Postmenopausal women with prediabetes (n=25, mean age 57) received 250 mg/day NMN or placebo for 10 weeks in a randomised, double-blind design. Skeletal muscle biopsies showed improved insulin signalling (specifically, enhanced insulin-stimulated AKT phosphorylation) and upregulation of genes involved in muscle NAD+ metabolism. Critically, blood NAD+ was not significantly elevated in the NMN group — a finding that suggests NMN may preferentially distribute to skeletal muscle in humans, raising intramuscular NAD+ without a proportionate increase in circulating levels. This has important implications for how practitioners interpret blood NAD+ tests in patients taking NMN.

Igarashi et al., 2022 (NPJ Aging): 12-week RCT, 250 mg/day NMN vs placebo in healthy older adults (n=30, ages 65–80). NMN supplementation improved gait speed and grip strength compared to placebo. Blood NAD+ was modestly elevated. This study provides the best current evidence for functional physical performance benefits of NMN in older adults, though the effect sizes were modest and the sample size small.

Irie et al., 2020 (Endocrine Journal): The first human safety and pharmacokinetics study for NMN. Healthy Japanese men received single oral doses of NMN (100, 250, or 500 mg). NMN was rapidly converted to circulating NAD+ metabolites. No adverse clinical signs, symptoms, or laboratory abnormalities were detected at any dose. Established the initial human safety profile.

Yi et al., 2023 (GeroScience): 60-day RCT in healthy adults with self-reported fatigue. NMN supplementation at 300 mg/day improved subjective fatigue scores, physical performance measures, and aerobic capacity (VO2 parameters) compared to placebo. Suggests potential benefit for physically active individuals and those with exercise-related fatigue.

5. NMN vs NR: Head-to-Head Comparison Table

| Parameter | NR (Nicotinamide Riboside) | NMN (Nicotinamide Mononucleotide) | |---|---|---| | Position in salvage pathway | 2 steps from NAD+ | 1 step from NAD+ | | Cellular uptake mechanism | ENT1/ENT2 transporters (confirmed) | Slc12a8 (mouse); may convert to NR first in humans | | Blood NAD+ elevation | 40–60% (well replicated across >5 RCTs) | Variable; lower in blood, potentially higher in muscle | | Key tissue specificity | Liver, whole blood (well established) | Skeletal muscle (Yoshino 2021) | | Human RCTs published | 6+ randomised controlled trials | 4–5 randomised controlled trials | | Functional outcomes | BP reduction (subgroup, Martens 2018) | Gait speed/grip strength (Igarashi 2022); insulin signalling (Yoshino 2021) | | Evidence strength | Stronger (more trials, larger n) | Emerging; mechanistically distinct | | Standard clinical dose | 500–1,000 mg/day | 250–500 mg/day | | Sublingual formulation available | No (standard oral capsule) | Yes (sublingual and liposomal available) | | Typical Australian retail cost | AUD $60–$100 per month (500 mg/day) | AUD $80–$140 per month (300–500 mg/day) | | Combination with pterostilbene | Yes (Elysium Basis formulation) | Common in stacks with resveratrol | | TGA regulatory status | Listed complementary medicine (AUST L) | Listed complementary medicine (AUST L) | | Safety ceiling (human data) | 2,000 mg/day (ChromaDex safety data) | 1,200 mg/day (Yi 2023, Irie 2020) |

6. Sublingual NMN: Does the Delivery Route Matter?

Sublingual NMN formulations — powder or lozenges held under the tongue for 1–2 minutes before swallowing — have become increasingly common in the Australian market. The rationale is direct absorption via the sublingual mucosa, bypassing first-pass hepatic metabolism and potentially increasing bioavailability compared to standard oral capsules.

The evidence base for sublingual NMN specifically is limited. There is no published head-to-head pharmacokinetic trial comparing sublingual versus oral NMN in humans. The theoretical basis is sound — sublingual absorption is an established delivery route for other small molecules (nitrates, buprenorphine) — but NMN's molecular characteristics (molecular weight 334 g/mol, charged at physiological pH) make transcellular sublingual absorption somewhat less certain than for smaller lipophilic compounds.

What practitioners should advise:

If a patient reports preferring sublingual NMN based on perceived faster onset or improved tolerability, this is clinically reasonable to continue — but should not be presented as evidence-based superiority over oral delivery. The published human RCT data that supports NMN's effects (Yoshino, Igarashi, Yi) used standard oral formulations. Extrapolating sublingual pharmacokinetics from these trials is not valid.

Cost is also a factor: sublingual NMN products typically carry a price premium of 20–40% over equivalent-dose oral capsules in the Australian market, without supporting clinical equivalence data to justify the difference on outcomes grounds.

7. Combination Strategies: Pterostilbene, Resveratrol, and the SIRT1 Hypothesis

Both NMN and NR are frequently sold in combination with stilbene polyphenols — primarily resveratrol and its more bioavailable analogue pterostilbene — based on the hypothesis that these compounds activate SIRT1, which then requires NAD+ as a co-substrate. The logic: raise NAD+ (via NR or NMN) and simultaneously activate the enzyme that uses it (via resveratrol/pterostilbene).

The evidence for this combination:

The original resveratrol-SIRT1 direct activation hypothesis, proposed by Howitz et al. (2003) and championed by David Sinclair, has been substantially challenged. Concerns include artifacts in the fluorescence-based assay used in early studies and failure to replicate direct SIRT1 activation by resveratrol in more rigorous in vitro systems. The in vivo resveratrol effects that have been replicated appear to occur through indirect mechanisms (AMPK activation, CD38 inhibition, PDE inhibition) rather than direct SIRT1 deacylase activation.

Pterostilbene (3,5-dimethoxy-4'-hydroxystilbene) has superior bioavailability to resveratrol (~80% vs ~1% oral bioavailability in animal models) due to two methoxy groups replacing the hydroxyl groups of resveratrol. It has demonstrated CD38 inhibitory activity in cell models — potentially reducing NAD+ degradation rather than directly activating sirtuins. If this mechanism operates in humans at achievable tissue concentrations, it could provide additive benefit to NR or NMN supplementation. However, human data specific to the pterostilbene + NAD precursor combination is limited to the Elysium Basis commercial research programme (NR + pterostilbene), which has not yet generated published RCT data on combination synergy.

Practitioner guidance: Combination products are not unreasonable from a mechanistic standpoint, but the clinical case for paying a premium for combination formulations over standalone NR or NMN is not established by published head-to-head trial data. For patients with limited budgets, a quality single-compound NR or NMN at an evidence-based dose is the more defensible starting point.

8. Who Benefits Most? Populations and Clinical Indications

Based on the available human trial evidence and mechanistic understanding, the following populations have the strongest case for NAD+ precursor supplementation:

Adults over 40 with metabolic concerns: The age-related NAD+ decline is measurable from the 40s onward. The Yoshino 2021 trial specifically recruited postmenopausal women with prediabetes, showing NMN's benefit in impaired insulin signalling — a common metabolic profile in this demographic. NR may be appropriate here as a first-line choice given its broader evidence base, with NMN as a reasonable alternative where muscle-specific effects are the clinical priority.

Individuals with high exercise demand: Yi et al. (2023) demonstrated improvements in aerobic performance markers and exercise-related fatigue with NMN. Active individuals — particularly those engaging in endurance training or experiencing exercise recovery issues — represent a plausible target population. NAD+'s role in mitochondrial energy production and PARP-mediated muscle repair during exercise training is mechanistically coherent. For a deeper look at how mitochondrial support compounds interact in this context, the CoQ10 and ubiquinol mitochondrial health guide covers complementary approaches for mitochondrial function optimisation.

Older adults with physical function decline: Igarashi et al. (2022) showed improvements in gait speed and grip strength — objective functional markers — in adults aged 65–80 taking 250 mg/day NMN. These are meaningful clinical endpoints with direct relevance to fall risk and functional independence.

Individuals with mitochondrial insufficiency or chronic fatigue presentations: NAD+'s central role in mitochondrial Complex I function makes precursor supplementation mechanistically rational in fatigue presentations with a suspected mitochondrial or metabolic component. This should be considered alongside other longevity-oriented cellular interventions — the autophagy and longevity protocol covers how caloric restriction and fasting interact with NAD+ biology via AMPK and mTOR, providing a complementary framework for practitioners approaching cellular health holistically.

Populations where evidence is thinner: Cognitive outcomes represent an area of active research interest but limited human RCT data. Animal studies demonstrate NAD+ precursors crossing the blood-brain barrier and improving neurological markers, but published human trials on cognitive outcomes in healthy adults are not yet available. Patients taking NMN or NR specifically for cognitive protection should understand this evidence gap.

9. Dose Reference: What Human Trials Support

NR Doses in Published Human RCTs:

250–500 mg/day: Safety threshold studies; minimal but measurable blood NAD+ elevation
500–1,000 mg/day: Standard range with consistent 40–60% blood NAD+ elevation; Martens 2018 used 1,000 mg/day
2,000 mg/day: Maximum studied in ChromaDex safety data; tolerable with mild GI effects possible

NMN Doses in Published Human RCTs:

250 mg/day: Yoshino 2021 (muscle insulin signalling), Igarashi 2022 (gait/grip strength) — lowest effective doses in published trials with positive functional outcomes
300 mg/day: Yi 2023 (fatigue and aerobic performance)
500–1,200 mg/day: Dose escalation and safety studies; no serious adverse events

Practical starting protocol: For new users, 250–500 mg/day of either compound is a reasonable starting dose. Duration of at least 8–12 weeks is required to assess any meaningful physiological response, consistent with the timelines used in positive trials. Assess both subjective markers (energy, recovery, exercise tolerance) and objective markers where possible (blood NAD+ or functional testing).

The stress axis and HPA burden also affect NAD+ metabolism — chronic stress drives inflammatory pathways that upregulate CD38 and accelerate NAD+ consumption. Supporting adrenal and stress resilience pathways can therefore complement NAD+ precursor therapy; the rhodiola rosea adaptogen research review covers evidence for adaptogens that address the cellular energy and stress-response interface.

10. Testing NAD+ Levels: What the Numbers Actually Mean

Two approaches are used in clinical and research settings to assess NAD+ status:

Blood NAD+ measurement: Whole blood or peripheral blood mononuclear cells (PBMCs) are the most accessible sample types. Specialist private laboratories in Australia (including some functional medicine labs) offer blood NAD+ panels, typically reporting NAD+, NADH, and NAD+/NADH ratios. Normal ranges are not yet standardised across laboratories, and reference intervals vary depending on the methodology used.

Critical caveat from the Yoshino 2021 trial: NMN supplementation raised muscle NAD+ without significantly raising blood NAD+. This means blood NAD+ measurement may fail to detect meaningful NAD+ elevation in skeletal muscle when NMN is the precursor used. Practitioners monitoring NMN therapy should therefore not rely solely on blood NAD+ elevation as a biomarker of response — functional endpoints (exercise tolerance, grip strength, energy) and metabolic markers (fasting insulin, HOMA-IR in at-risk populations) may be more informative.

NAMPT enzyme activity: NAMPT is the rate-limiting enzyme in the salvage pathway and is measurable in blood via specialised assays. NAMPT activity gives a proxy for the efficiency of endogenous NAD+ biosynthesis — reduced NAMPT activity suggests supplementation is addressing a genuine bottleneck. However, NAMPT assays are not widely available in routine clinical settings in Australia at present.

Practical approach for patients: Where laboratory testing is not accessible or cost-effective, a structured n=1 self-trial with clear pre-specified endpoints (energy ratings, exercise performance metrics, body composition changes over 12 weeks) is a clinically reasonable monitoring approach. Document baseline, intervene at a consistent dose, and reassess at 12 weeks before drawing conclusions.

Where gut absorption is a clinical concern — for example in patients with inflammatory bowel conditions or documented dysbiosis — the GI-MAP interpretation guide covers functional stool testing approaches that can identify gut-level factors relevant to oral supplement absorption efficiency.

11. Australian Market and Regulatory Context

TGA Regulatory Status

In Australia, both NMN and NR are regulated as listed complementary medicines under the Therapeutic Goods Administration (TGA) framework. Listed medicines (AUST L number) are assessed for safety and quality but are not individually assessed for efficacy — manufacturers must hold evidence supporting any therapeutic claims made, but that evidence is not reviewed by the TGA at listing. This is standard for the complementary medicines category and means consumers should independently assess the quality of underlying trial data rather than relying on TGA listing as an efficacy endorsement.

NMN's regulatory status globally has been dynamic: the US FDA issued letters in 2022 questioning whether NMN could be marketed as a dietary supplement given prior clinical investigation, and the situation has continued to evolve. In Australia, NMN has continued to be listed and sold as a complementary medicine without the same regulatory ambiguity that affected the US market.

Quality Considerations in the Australian Market

Third-party testing matters significantly in the NAD+ precursor category. Purity and stability are non-trivial concerns: NMN in particular is susceptible to degradation when exposed to heat, moisture, or light, and some products available in the Australian market have shown variable NMN content on independent assay. When selecting a product, look for:

Certificate of Analysis (CoA) from an independent third-party laboratory
Stability testing data, particularly for sublingual or powder formulations
GMP (Good Manufacturing Practice) certification of the manufacturing facility
Clear disclosure of active ingredient content per serve in milligrams

For practitioners and informed consumers seeking products that meet these standards, practitioner-grade NAD precursor supplements with third-party quality documentation are available from suppliers operating under dispensary-grade standards.

Cost Comparison (Australian Market, 2026)

NR is generally less expensive than NMN per milligram in the Australian retail market. At standard clinical doses:

NR 500 mg/day: approximately AUD $60–$100 per month for quality-branded products
NMN 300–500 mg/day: approximately AUD $80–$140 per month depending on formulation type

Sublingual and liposomal NMN formulations carry a further price premium of 20–40%. For patients on tight budgets, NR represents better value for documented blood NAD+ elevation, while NMN's muscle-specific benefits may justify the cost differential for patients with musculoskeletal, metabolic, or exercise performance priorities.

12. Frequently Asked Questions

Q: Which is better for longevity — NMN or NR?

There is no definitive answer from published human RCTs. NR has a larger body of human trial evidence and consistently raises blood NAD+. NMN has shown promising muscle-specific effects (Yoshino 2021) and functional improvements in older adults (Igarashi 2022). No head-to-head RCT in humans has directly compared the two with clinical outcome measures. For a general longevity-oriented protocol in adults over 40, NR is the more evidence-anchored starting choice. For muscle-specific, metabolic, or exercise performance goals, NMN is a well-supported alternative.

Q: What dose of NMN or NR should I take?

Published human trials showing positive outcomes have used 250–500 mg/day of NMN and 500–1,000 mg/day of NR. Starting at the lower end (250–500 mg/day for either compound) for 8–12 weeks is prudent for new users, with titration based on clinical response. Doses above 1,000 mg/day do not have proportionally stronger evidence for additional benefit and increase cost without clear justification from published trial data.

Q: Does David Sinclair's NMN protocol mean NMN is better than NR?

David Sinclair (Harvard Medical School) publicly states that he takes 1 g/day NMN personally and has described his broader stack in media interviews. His laboratory's published animal research established important mechanistic foundations for NMN. However, his personal supplement use and public commentary should be distinguished from published human RCT evidence, which does not conclusively demonstrate NMN superiority over NR for longevity outcomes in humans. The resveratrol component of his stack is based on mechanisms that have been substantially challenged in subsequent research. The metformin component may also blunt exercise-induced NAD+ responses — a concern for physically active individuals.

Q: Can I get a blood test for NAD+ levels in Australia?

Yes — some functional medicine and integrative health laboratories in Australia offer blood NAD+ panels. However, be aware that blood NAD+ measurement may not accurately reflect muscle NAD+ status when using NMN (Yoshino 2021 showed muscle elevation without proportionate blood elevation). Standard reference ranges are also not yet well established, making result interpretation context-dependent. Discuss with a practitioner experienced in interpreting functional laboratory results before acting on these numbers in isolation.

Q: Are there any interactions or contraindications I should know about?

NAD+ precursors are generally well tolerated at recommended doses. Key points: high-dose nicotinamide (niacinamide) — which is distinct from NR and NMN — inhibits sirtuin activity at elevated concentrations; this concern does not apply to NR or NMN at typical doses. Metformin combined with NAD+ precursors may blunt exercise-induced NAD+ elevation via Complex I inhibition — a potential concern for physically active patients. Patients undergoing chemotherapy or those with significant hepatic impairment should consult their specialist before starting NAD+ precursor supplementation. Mild GI sensitivity at higher doses (>1,000 mg/day) is the most commonly reported adverse effect for both compounds across published trials.

Summary: Making the Clinical Decision

The practical NMN vs NR decision comes down to primary clinical goals:

Blood NAD+ elevation with the strongest evidence base → NR 500–1,000 mg/day
Skeletal muscle NAD+ and insulin sensitivity → NMN 250–500 mg/day (Yoshino 2021)
Physical function in adults aged 65+ → NMN 250 mg/day (Igarashi 2022)
Exercise performance and fatigue → NMN 300 mg/day (Yi 2023)
Budget priority with sound evidence → NR at standard dose

Both compounds are well-tolerated, available in Australia as listed complementary medicines, and supported by human trial evidence at doses of 250–1,000 mg/day. Neither has demonstrated lifespan extension or reversal of aging in humans — the evidence is for more modest, clinically meaningful improvements in specific physiological markers and functional outcomes in defined populations.

Product quality matters. In a supplementation category where purity and stability vary across the market, third-party tested formulations with documented CoA and GMP manufacturing are the appropriate standard before committing to a 12-week protocol.

This article is for educational and informational purposes only. It does not constitute medical or clinical advice. NAD+ precursor supplementation should be discussed with a qualified naturopathic or integrative medicine practitioner in the context of your individual health history, current medications, and clinical goals. The evidence base for NMN and NR continues to evolve — consult current literature and your practitioner before making supplementation decisions.